GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (STU:HBI) » Definitions » Cyclically Adjusted Revenue per Share

Harvard Bioscience (STU:HBI) Cyclically Adjusted Revenue per Share : €3.09 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Harvard Bioscience Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Harvard Bioscience's adjusted revenue per share for the three months ended in Mar. 2024 was €0.520. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.09 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Harvard Bioscience's average Cyclically Adjusted Revenue Growth Rate was -2.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -0.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Harvard Bioscience was 8.10% per year. The lowest was -0.20% per year. And the median was 1.30% per year.

As of today (2024-06-20), Harvard Bioscience's current stock price is €2.64. Harvard Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €3.09. Harvard Bioscience's Cyclically Adjusted PS Ratio of today is 0.85.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Harvard Bioscience was 2.42. The lowest was 0.42. And the median was 1.16.


Harvard Bioscience Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Harvard Bioscience's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience Cyclically Adjusted Revenue per Share Chart

Harvard Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.95 2.62 3.08 2.90 3.06

Harvard Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.14 3.22 3.17 3.06 3.09

Competitive Comparison of Harvard Bioscience's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Bioscience's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's Cyclically Adjusted PS Ratio falls into.



Harvard Bioscience Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Harvard Bioscience's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.52/131.7762*131.7762
=0.520

Current CPI (Mar. 2024) = 131.7762.

Harvard Bioscience Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.602 100.560 0.789
201409 0.591 100.428 0.775
201412 0.732 99.070 0.974
201503 0.723 99.621 0.956
201506 0.733 100.684 0.959
201509 0.676 100.392 0.887
201512 0.767 99.792 1.013
201603 0.712 100.470 0.934
201606 0.682 101.688 0.884
201609 0.649 101.861 0.840
201612 0.728 101.863 0.942
201703 0.489 102.862 0.626
201706 0.486 103.349 0.620
201709 0.451 104.136 0.571
201712 0.524 104.011 0.664
201803 0.612 105.290 0.766
201806 0.748 106.317 0.927
201809 0.664 106.507 0.822
201812 0.798 105.998 0.992
201903 0.663 107.251 0.815
201906 0.694 108.070 0.846
201909 0.655 108.329 0.797
201912 0.734 108.420 0.892
202003 0.561 108.902 0.679
202006 0.538 108.767 0.652
202009 0.524 109.815 0.629
202012 0.654 109.897 0.784
202103 0.570 111.754 0.672
202106 0.604 114.631 0.694
202109 0.619 115.734 0.705
202112 0.718 117.630 0.804
202203 0.634 121.301 0.689
202206 0.649 125.017 0.684
202209 0.653 125.227 0.687
202212 0.645 125.222 0.679
202303 0.654 127.348 0.677
202306 0.627 128.729 0.642
202309 0.557 129.860 0.565
202312 0.605 129.419 0.616
202403 0.520 131.776 0.520

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Harvard Bioscience  (STU:HBI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Harvard Bioscience's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.64/3.09
=0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Harvard Bioscience was 2.42. The lowest was 0.42. And the median was 1.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Harvard Bioscience Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Bioscience (STU:HBI) Business Description

Traded in Other Exchanges
Address
84 October Hill Road, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.